Loading news...
Cinctive Capital Management LP purchased a new position in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 95,308 shares of the biopharmaceutical company's stock, valued at approximately $5,849,000. Cinctive Capital Management LP owned about 0.12% of PTC
WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.
PTC Therapeutics, Inc. (PTCT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Leerink Global Healthcare Conference 2026 Transcript
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Elliott Boulding sold 3,019 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $69.48, for a total transaction of $209,760.12. Following the sale, the vice president directly owned 105,212 shares in the company,
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and strong pricing power in ultra-rare disease markets.
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CAO Christine Marie Utter sold 2,494 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $172,983.84. Following the completion of the sale, the chief accounting officer directly owned
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) EVP Lee Scott Golden sold 2,484 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $172,290.24. Following the transaction, the executive vice president directly owned 89,944 shares
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CEO Matthew Klein sold 7,371 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the transaction, the chief executive officer owned 387,082 shares in the
Brummer Multi Strategy AB purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 19,142 shares of the biopharmaceutical company's stock, valued at approximately $1,175,000. PTC Therapeutics makes up 21.4%
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.
Besides Wall Street's top-and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review.
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.